Irucalantide

Irucalantide is kallikrein inhibitor[1].

Product Specifications

CAS Number

[1631160-47-8]

UNSPSC

12352209

Target

Ser/Thr Protease

Type

Peptides

Related Pathways

Metabolic Enzyme/Protease

Applications

Metabolism-protein/nucleotide metabolism

Field of Research

Others

Assay Protocol

https://www.medchemexpress.com/irucalantide.html

Purity

99.88

Solubility

DMSO : 100 mg/mL (ultrasonic)

Smiles

O=C(N[C@H](C(N[C@H](C(N[C@@](C(N[C@H](CN[C@H](C(N[C@H](C(N[C@H](C1=O)CC(O)=O)=O)CCC(N)=O)=O)CC2=CN=CN2)C)=O)([H])CSCC3=CC4=CC(CSC[C@H](NC([C@@H](N1)CC(C)C)=O)C(N)=O)=C3)=O)CCCCNC(N)=N)=O)CC(C=C5)=CC=C5O)[C@@](CC6)([H])N6C([C@@H](NC([C@@H](NC([C@H](CSC4)NC(C)=O)=O)CO)=O)CC7=CC=CC=C7)=O

Molecular Formula

C76H106N20O18S3

Molecular Weight

1683.97

References & Citations

[1]Teufel DP, et al. Stable and Long-Lasting, Novel Bicyclic Peptide Plasma Kallikrein Inhibitors for the Treatment of Diabetic Macular Edema. J Med Chem. 2018 Apr 12;61 (7) :2823-2836.